AC IMMUNE SA Share Price Today: Live Updates & Key Insights

AC IMMUNE SA share price today is $2.855, up -3.39%. The stock opened at $2.93 against the previous close of $2.95, with an intraday high of $2.98 and low of $2.835.

AC IMMUNE SA Share Price Chart

AC IMMUNE SA

us-stock
To Invest in {{usstockname}}
us-stock

AC IMMUNE SA Share Price Performance

$2.855 -0.0339(-3.39%) ACIU at 23 Mar 2026 11:52 AM Biotechnology
Lowest Today 2.835
Highest Today 2.98
Today’s Open 2.93
Prev. Close 2.95
52 Week High 4.00
52 Week Low 1.43
Day’s Range: Low 2.835 High 2.98
52-Week Range: Low 1.43 High 4.00
1 day return -
1 Week return -8.28
1 month return +14.28
3 month return -9.43
6 month return +13.38
1 year return +37.14
3 year return +32.11
5 year return -62.74
10 year return -

AC IMMUNE SA Institutional Holdings

Bvf Inc 19.70

Wells Fargo & Co 1.00

Millennium Management LLC 0.93

Renaissance Technologies Corp 0.66

iShares Biotechnology ETF 0.46

Acadian Asset Management LLC 0.41

BlackRock Inc 0.41

Arrowstreet Capital Limited Partnership 0.37

Northern Trust Corp 0.28

Deutsche Bank AG 0.25

Dimensional Fund Advisors, Inc. 0.21

Marshall Wace Asset Management Ltd 0.19

Susquehanna International Group, LLP 0.15

Dauntless Investment Group, LLC 0.12

Monega ARIAD Innovation R 0.09

Morgan Stanley - Brokerage Accounts 0.09

Two Sigma Investments LLC 0.09

iShares Nasdaq US Biotech ETF USD Acc 0.07

Citadel Advisors Llc 0.07

Fidelity Nasdaq Composite Index 0.06

Geode Capital Management, LLC 0.06

Dimensional US Small Cap ETF 0.06

DFA US Small Cap I 0.04

Top Class Healthcare FI 0.04

DFA US Micro Cap I 0.03

China Universal NASDAQ Bio-Tch ETF(QDII) 0.02

China Universal Asset Mgmt Co.Ltd 0.02

UBS Group AG 0.02

SEI Investments Co 0.02

DFA US Vector Equity I 0.02

DFA US Vector Equity Class F 0.01

Dimensional Global Small Coms USD Acc 0.01

Dimensional World Equity GBP Acc 0.01

Voya Multi-Manager International Sm Cp A 0.01

Dimensional International Core Eq Acc 0.01

Old Westbury Small & Mid Cap Strategies 0.01

Dimensional US Core Equity Market ETF 0.01

JNL/DFA US Small Cap A 0.01

Dimensional US Core Equity 2 ETF 0.01

Dimensional World Allc 60/40 GBP Acc 0.01

AC IMMUNE SA Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

AC IMMUNE SA Fundamentals

Market Cap 286.71 M

PB Ratio 5.1913

PE Ratio 0.0

Enterprise Value 178.14 M

Total Assets 154.43 M

Volume 232833

AC IMMUNE SA Company Financials

Annual Revenue FY23:1000 0.0M, FY22:3935000 3.9M, FY21:0 0.0M, FY20:15431000 15.4M, FY19:111026000 111.0M

Annual Profit FY23:null 0.0M, FY22:3935000 3.9M, FY21:null 0.0M, FY20:15431000 15.4M, FY19:111026000 111.0M

Annual Net worth FY23:-68238000 -68.2M, FY22:-70753000 -70.8M, FY21:-72996000 -73.0M, FY20:-62105000 -62.1M, FY19:45442000 45.4M

Quarterly Revenue Q3/2025:939000 0.9M, Q2/2025:1306000 1.3M, Q1/2025:990000 1.0M, Q3/2024:25485000 25.5M, Q2/2024:687000 0.7M

Quarterly Profit Q3/2025:939000 0.9M, Q2/2025:1306000 1.3M, Q1/2025:990000 1.0M, Q3/2024:25485000 25.5M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-15858000 -15.9M, Q2/2025:-21189000 -21.2M, Q1/2025:-19029000 -19.0M, Q3/2024:5503000 5.5M, Q2/2024:-22760000 -22.8M

About AC IMMUNE SA & investment objective

Company Information AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Organisation Biotechnology

Employees 90

Industry Biotechnology

CEO Dr. Andrea Pfeifer Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

AC IMMUNE SA FAQs

What is the share price of AC IMMUNE SA today?

The current share price of AC IMMUNE SA is $2.855.

Can I buy AC IMMUNE SA shares in India?

Yes, Indian investors can buy AC IMMUNE SA shares by opening an international trading and demat account with Motilal Oswal.

How to buy AC IMMUNE SA shares in India?

You can easily invest in AC IMMUNE SA shares from India by:

Can I buy fractional shares of AC IMMUNE SA?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of AC IMMUNE SA?

AC IMMUNE SA has a market cap of $286.71 M.

In which sector does AC IMMUNE SA belong?

AC IMMUNE SA operates in the Biotechnology sector.

What documents are required to invest in AC IMMUNE SA stocks?

To invest, you typically need:

What is the PE and PB ratio of AC IMMUNE SA?

The PE ratio of AC IMMUNE SA is N/A and the PB ratio is 5.19.